AU2002229573A1 - Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives - Google Patents
Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivativesInfo
- Publication number
- AU2002229573A1 AU2002229573A1 AU2002229573A AU2957302A AU2002229573A1 AU 2002229573 A1 AU2002229573 A1 AU 2002229573A1 AU 2002229573 A AU2002229573 A AU 2002229573A AU 2957302 A AU2957302 A AU 2957302A AU 2002229573 A1 AU2002229573 A1 AU 2002229573A1
- Authority
- AU
- Australia
- Prior art keywords
- prostaglandins
- pyrimidines
- antagonists
- calcium
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10063224A DE10063224A1 (en) | 2000-12-19 | 2000-12-19 | Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin |
DE10063224 | 2000-12-19 | ||
DE10063882 | 2000-12-21 | ||
DE2000163882 DE10063882A1 (en) | 2000-12-21 | 2000-12-21 | Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin |
DE2000164993 DE10064993A1 (en) | 2000-12-23 | 2000-12-23 | Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin |
DE10064993 | 2000-12-23 | ||
PCT/EP2001/013916 WO2002049651A1 (en) | 2000-12-19 | 2001-11-28 | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002229573A1 true AU2002229573A1 (en) | 2002-07-01 |
Family
ID=27214208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002229573A Abandoned AU2002229573A1 (en) | 2000-12-19 | 2001-11-28 | Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040063730A1 (en) |
EP (1) | EP1343506A1 (en) |
JP (1) | JP2004516270A (en) |
KR (1) | KR20030059349A (en) |
CN (1) | CN1481244A (en) |
AR (1) | AR035676A1 (en) |
AU (1) | AU2002229573A1 (en) |
BR (1) | BR0115995A (en) |
CA (1) | CA2431077A1 (en) |
CZ (1) | CZ20031776A3 (en) |
HU (1) | HUP0303315A2 (en) |
MX (1) | MXPA03005393A (en) |
NO (1) | NO20032773D0 (en) |
PL (1) | PL362513A1 (en) |
SK (1) | SK8192003A3 (en) |
WO (1) | WO2002049651A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035531A1 (en) * | 2001-01-22 | 2004-06-02 | Novartis Ag | COMPOSITION FOR THE CONTROL OF ENDOPARASITIC PESTS IN LIVESTOCK AND DOMESTIC ANIMALS, A METHOD FOR THEIR CONTROL AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF MEDICINES |
ATE478872T1 (en) * | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | PYRAZOLOA4,3-DÜPYRIMIDINES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC USE |
DE10229778A1 (en) * | 2002-07-03 | 2004-01-29 | Bayer Ag | New use of imidazotriazinones |
FR2842809A1 (en) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOVEL SUBSTITUTED PYRAZOLO [1,5-a] -1,3,5-TRIAZINES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, USE AS A MEDICAMENT AND METHODS FOR THEIR PREPARATION |
KR100468352B1 (en) * | 2002-09-24 | 2005-01-27 | 한국과학기술연구원 | New pyrazolopyrimidine derivatives, process for their preparation and pharmaceutical composition comprising the same |
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
DK1628663T3 (en) * | 2003-05-15 | 2010-03-08 | Roskamp Res Llc | Process for the preparation of medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
EP1742950B1 (en) * | 2004-04-07 | 2008-12-17 | Pfizer Limited | Pyrazolo[4,3-d] pyrimidines |
CA2681582C (en) | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
CA2701620C (en) * | 2007-10-05 | 2014-12-09 | Alzheimer's Institute Of America, Inc. | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
NO2315587T3 (en) * | 2008-08-13 | 2018-03-24 | ||
TWI725008B (en) * | 2015-01-28 | 2021-04-21 | 瑞采生技有限公司 | COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF |
AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TW201811799A (en) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | Pyrazolopyrimidine compounds and uses thereof |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
MX2019012431A (en) * | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Indole ahr inhibitors and uses thereof. |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators |
KR20200133747A (en) | 2018-02-20 | 2020-11-30 | 인사이트 코포레이션 | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for treating cancer |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
KR20220059480A (en) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | HPK1 inhibitor in solid form |
EP4065582A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2353285A1 (en) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action |
JPS5459266A (en) * | 1977-10-14 | 1979-05-12 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analogs and their preparation |
FR2568774B2 (en) * | 1984-05-30 | 1989-05-19 | Choay Sa | DRUGS THAT PROMOTE BLOOD FLOW PROPERTIES AND THEIR THERAPEUTIC USE |
FR2672601B1 (en) * | 1991-02-08 | 1994-10-14 | Synthelabo | BENZO-1,5-THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
DE19709877A1 (en) * | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives |
CA2305394C (en) * | 1997-10-28 | 2006-12-12 | Vivus, Incorporated | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
DE19942474A1 (en) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo [4,3-d] pyrimidines |
DE10058662A1 (en) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Use of pyrazolo [4,3-d] pyrimidines |
DE10103647A1 (en) * | 2001-01-27 | 2002-08-01 | Merck Patent Gmbh | Process for the preparation of a pyrazolo (4,3-d) pyrimidine derivative |
-
2001
- 2001-11-28 WO PCT/EP2001/013916 patent/WO2002049651A1/en not_active Application Discontinuation
- 2001-11-28 CN CNA018209165A patent/CN1481244A/en active Pending
- 2001-11-28 SK SK819-2003A patent/SK8192003A3/en unknown
- 2001-11-28 US US10/451,105 patent/US20040063730A1/en not_active Abandoned
- 2001-11-28 HU HU0303315A patent/HUP0303315A2/en unknown
- 2001-11-28 JP JP2002550991A patent/JP2004516270A/en active Pending
- 2001-11-28 EP EP01990452A patent/EP1343506A1/en not_active Withdrawn
- 2001-11-28 KR KR10-2003-7008078A patent/KR20030059349A/en not_active Application Discontinuation
- 2001-11-28 CZ CZ20031776A patent/CZ20031776A3/en unknown
- 2001-11-28 PL PL01362513A patent/PL362513A1/en unknown
- 2001-11-28 BR BR0115995-0A patent/BR0115995A/en not_active Application Discontinuation
- 2001-11-28 CA CA002431077A patent/CA2431077A1/en not_active Abandoned
- 2001-11-28 AU AU2002229573A patent/AU2002229573A1/en not_active Abandoned
- 2001-11-28 MX MXPA03005393A patent/MXPA03005393A/en not_active Application Discontinuation
- 2001-12-19 AR ARP010105888A patent/AR035676A1/en unknown
-
2003
- 2003-06-18 NO NO20032773A patent/NO20032773D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2431077A1 (en) | 2002-06-27 |
JP2004516270A (en) | 2004-06-03 |
US20040063730A1 (en) | 2004-04-01 |
PL362513A1 (en) | 2004-11-02 |
CN1481244A (en) | 2004-03-10 |
CZ20031776A3 (en) | 2003-09-17 |
NO20032773L (en) | 2003-06-18 |
EP1343506A1 (en) | 2003-09-17 |
WO2002049651A1 (en) | 2002-06-27 |
BR0115995A (en) | 2004-01-13 |
AR035676A1 (en) | 2004-06-23 |
NO20032773D0 (en) | 2003-06-18 |
SK8192003A3 (en) | 2003-10-07 |
MXPA03005393A (en) | 2003-09-25 |
KR20030059349A (en) | 2003-07-07 |
HUP0303315A2 (en) | 2004-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002229573A1 (en) | Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives | |
AU2001291893A1 (en) | Use of substituted imidazo(1,2-a)pyridine-, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine-3-yl-amine derivatives for producing NOS-inhibiting medicaments | |
SI1220856T1 (en) | Pyrazolo(4,3-d)pyrimidine derivatives | |
HUP0400692A3 (en) | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them | |
HUP0103472A3 (en) | Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same | |
EP1416935B8 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
AU7727400A (en) | Traction fluid formulation | |
DK1382339T3 (en) | Compositions containing pyrrolo 2,3-d pyrimidine derivatives | |
ZA9811178B (en) | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors. | |
AU2002238947A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | |
SI0891978T1 (en) | 5H-Thiazolo (3,2-a) pyrimidine derivatives | |
AU2001292185A1 (en) | Formulation containing amoxicillin | |
AU7588696A (en) | Pyrido{2, 3-D} pyrimidine derivatives and pharmaceutical compositions thereof | |
HUP0002902A3 (en) | 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions | |
IL156536A0 (en) | Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same | |
AU2002361407A1 (en) | Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof | |
AU4207197A (en) | 3-substituted pyrido(4',3':4,5)thieno(2,3-d)pyrimidine derivatives, their preparation and their use | |
AU5491699A (en) | Process for the preparation of pyrrolo(2,3-d)pyrimidines | |
PL340734A1 (en) | Fungicidal compositions containing derivatives of thiene [2.3-d] pyrimidin-4-one | |
AU2002215979A1 (en) | Use of pyrazolo(4,3-D)pyrimidines | |
AU1223400A (en) | Novel pterin antineoplastic agents | |
AU2002216033A1 (en) | Use of pyrazolo(4,3-d)pyrimidines | |
HUP0002736A3 (en) | 3-substituted pyrido [3',4':4,5]thieno[2,3-d]pyrimidine derivatives, and their use for the preparation of pharmaceutical compositions | |
AU2002226362A1 (en) | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | |
HUP0400443A3 (en) | Pyrazolo[1,2-a][1,2,4]triazole compounds useful as anti-inflammatory agents and pharmaceutical compositions containing them |